Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · IEX Real-Time Price · USD
8.43
-0.18 (-2.09%)
At close: Jul 2, 2024, 4:00 PM
8.48
+0.05 (0.59%)
After-hours: Jul 2, 2024, 6:44 PM EDT
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for INO stock have an average target of 20.75, with a low estimate of 11 and a high estimate of 40. The average target predicts an increase of 146.14% from the current stock price of 8.43.
Analyst Consensus: Buy
* Price targets were last updated on May 14, 2024.
Analyst Ratings
The average analyst rating for INO stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Initiates $20 | Buy | Initiates | $20 | +137.25% | May 14, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $40 | Buy | Maintains | $40 | +374.50% | Mar 8, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $11 | Hold | Reiterates | $11 | +30.49% | Mar 7, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $4 | Hold → Buy | Upgrades | $4 | -52.55% | Jan 25, 2024 |
| JMP Securities | JMP Securities | Buy Initiates $12 | Buy | Initiates | $12 | +42.35% | Jan 4, 2024 |
Financial Forecast
Revenue This Year
351.65K
from 832.01K
Decreased by -57.73%
Revenue Next Year
20.00M
from 351.65K
Increased by 5,587.45%
EPS This Year
-4.47
from -6.09
EPS Next Year
-3.22
from -4.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 630,000 | 79.0M | 249.8M | 524.1M | 950.8M |
| Avg | 351,652 | 20.0M | 78.8M | 177.0M | 324.4M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -24.3% | 22,354.0% | 1,148.9% | 564.7% | 437.1% |
| Avg | -57.7% | 5,587.4% | 294.2% | 124.5% | 83.3% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.05 | -1.84 | 0.84 | 7.38 | 17.09 |
| Avg | -4.47 | -3.22 | -1.51 | 0.93 | 4.03 |
| Low | -4.92 | -3.96 | -3.05 | -2.13 | -1.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 1,739.6% |
| Avg | - | - | - | - | 333.4% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.